Analyst Research

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: Pechala's Reports
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Sanofi SA's Sanofi Pasteur Announces Acceptance of Quadrivalent Influenza Vaccine for Review for European Approval


Thursday, 11 Apr 2013 01:00am EDT 

Sanofi SA's Sanofi Pasteur announced that a decentralized marketing authorization application has been accepted for review in the European Union countries for a quadrivalent (four-strain) formulation of Vaxigrip Sanofi Pasteur’s seasonal inactivated split-virion influenza vaccine produced at its facility in Val de Reuil, France. The file has been accepted for review by France’s Agence nationale de securite du medicament et des produits de sante (ANSM) as the regulatory agency for the “Reference Member State”, and by national regulatory agencies from the EU countries. 

Company Quote

75.48
0.71 +0.95%
17 Apr 2014